In a retrospective study, we compared the incidence and risk of mortality associated with CMV disease in adult allogeneic BMT and PBSC recipients who received ganciclovir prophylaxis three-times-per-week (78 patients) vs five-times-per-week (137 patients). Active CMV infection occurred in 28 (41%) and 26 (21%) in the threevs five-times-per-week groups, respectively (P Ͻ 0.005). CMV disease developed in 11 (16%) and five (4%) patients who received ganciclovir prophylaxis in the three-times-per-week vs five-times-per-week groups (P Ͻ 0.004). The CMV-attributable mortality rate was 1.5% and 12% in the five-vs three-times-per-week groups, respectively (P Ͻ 0.003). Risk factors for CMV disease, significant at the P Ͻ 0.05 level in the multivariate analysis, were ganciclovir prophylaxis at threetimes-per-week, receiving a T cell-depleted (TCD) marrow, and tacrolimus as prophylaxis for GVHD. These data suggest that ganciclovir five-times-per-week significantly reduced the incidence and mortality of CMV disease in allogeneic BMT and PBSC recipients. However, ganciclovir five-times-per-week was less effective for the prevention of CMV disease in patients receiving TCD marrow or tacrolimus. Keywords: cytomegalovirus; allogeneic marrow transplant; ganciclovir; T cell depletion; tacrolimus; FK506 Ganciclovir has been shown to be clinically effective for the prevention and treatment of cytomegalovirus (CMV) infection in a variety of immunocompromised hosts. Ganciclovir has been used for the prevention or treatment of CMV disease in heart, 1-5 heart-lung, 6,7 lung, 3,8 liver 3, 9, 10 and renal transplant recipients.
Ganciclovir has been shown to be clinically effective for the prevention and treatment of cytomegalovirus (CMV) infection in a variety of immunocompromised hosts. Ganciclovir has been used for the prevention or treatment of CMV disease in heart, [1] [2] [3] [4] [5] heart-lung, 6 ,7 lung, 3, 8 liver 3, 9, 10 and renal transplant recipients. 3, 10, 11 There have been several studies suggesting the efficacy of ganciclovir when given as pre-emptive or prophylactic therapy. 12, 13 Patients given ganciclovir pre-emptively with laboratory evidence of on-going CMV replication have shown reduced CMV disease mortality 14, 15 and in one study, overall transplant mortality. 15 Ganciclovir has also been given at engraftment to 'a-risk' CMV seropositive patients or patients who are receiving CMV seropositive marrow. These studies have shown a decrease in the incidence of CMV infection and disease but no change in transplant mortality. 13, 16, 17 More recently, a trial was performed comparing CMV antigenemia-triggered pre-emptive therapy vs ganciclovir prophylaxis which showed an increase in CMV disease in the pre-emptive therapy group but no difference in transplant mortality due to an increase in invasive fungal infections in the prophylaxis group. 18 Both pre-emptive and prophylactic therapy are effective for preventing CMV disease, but questions remain about the optimal dose and schedule while minimizing toxicity. Different clinical practices have included giving ganciclovir from three to seven times per week. One observational study has suggested that giving ganciclovir three times per week to TCD-depleted marrow transplant patients is not effective therapy. 19 We compared the incidence and mortality of CMV disease in allogeneic BMT and PBSC recipients who received a three-times-per-week ganciclovir prophylaxis regimen with those who received a five-timesper-week regimen. We also defined risk factors for CMV disease in allogeneic marrow transplant patients while receiving ganciclovir prophylaxis.
Patients and methods

Patient population
We reviewed the medical records of all patients older than 16 years of age who received an allogeneic BMT or PBSC at the University of Texas MD Anderson Cancer Center between March 1991 and September 1994. Data were collected from 10 days pre-transplant to 100 days post-transplant or until death. Patients who received more than one transplant or received less than 72 h of ganciclovir prophylaxis were excluded from the study.
CMV prophylaxis
All patients who were CMV seropositive or had a CMV seropositive donor received ganciclovir prophylaxis. From March 1991 to April 1992, ganciclovir was given at a dose of 5 mg/kg i.v. three times per week beginning 30 days after transplant. In May 1992, patients who received a T cell-depleted marrow (TCD) were given ganciclovir prophylaxis at a dose of 5 mg/kg i.v. five-times-per-week. The regimen was introduced when the patient's absolute neutrophil count (ANC) reached 1500 cells/m 3 for 3 consecutive days. Beginning in October 1992, all patients received ganciclovir 5 mg/kg five-times-per-week. Foscarnet was used if the patient's ANC had not reached 1500 cells/m 3 within 30 days post transplant or if ganciclovir was discontinued because of toxic effects.
CMV infection and disease
Weekly blood buffy-coat and urine cultures or shell-vial assays were undertaken for all patients from 8 days pretransplant to 100 days post-transplant to monitor CMV infection. CMV viremia was routinely treated with a 2 week course of ganciclovir at 5 mg/kg i.v. every 12 h. CMV viruria was treated at the discretion of the primary physician.
CMV disease was defined as recovery of virus from a sterile, visceral site (eg liver, gastrointestinal system, bronchoalveolar lavage fluid) or histopathological evidence of CMV in a patient with clinical and radiological signs and symptoms compatible with CMV disease. Patients with CMV disease were treated with a 2 week course of ganciclovir at 5 mg/kg i.v. every 12 h or foscarnet 50 mg/kg i.v. every 8 h. Acute GVHD was graded in accordance with the Consensus Conference on acute GVHD. 20 
Statistical analysis
The incidence of CMV infection and disease was analyzed from the day of introduction of ganciclovir prophylaxis to 100 days post transplant. Risk factors for CMV disease were analyzed prior to the onset of CMV disease, regardless of the day ganciclovir prophylaxis was introduced. Univariate comparison of the time to events was performed by the method of Kaplan-Meier 21 and analyzed by the logrank test. 22 Proportional-hazards regression techniques were used to analyze risk factors for CMV disease. 23 Covariates included in the analysis were age, disease, peripheral blood stem cell transplant, T cell depletion, CMV serology, HLA-matched transplant, acute GVHD, FK506, and ganciclovir schedule.
Results
A total of 328 adult patients received an allogeneic BMT or PBSC from March 1991 to September 1994. One hundred and thirteen patients were excluded from the study. These included 49 CMV seronegative recipient/donor pairs, 32 patients who died in the early post-transplant period of non-CMV causes, 13 patients who received two BMTs, six patients who failed to engraft, four patients started on foscarnet at engraftment, one patient with renal failure, three patients who did not receive at least 72 h of ganciclovir prophylaxis, three patients who developed CMV disease prior to the introduction of ganciclovir prophylaxis, and two patients with incomplete medical records. All three patients who developed disease prior to the start of ganciclovir prophylaxis were diagnosed with CMV pneumonia. Two patients diagnosed with CMV pneumonia were being treated with acyclovir for mucocutaneous herpes simplex disease and suspected herpes simplex encephalitis, respectively, and did not receive ganciclovir prophylaxis. The third patient developed CMV pneumonia on day 19 after transplant prior to the initiation of ganciclovir prophylaxis.
Of the 215 patients, 78 (36%) received three-times-perweek and 137 (64%) received five-times-per-week ganciclovir prophylaxis (Table 1 ). There were some important differences between the two different treatment regimens reflecting changes in the patient population during the study period. Patients in the five-times-per-week group were slightly older (median 38 vs 34 years, P = 0.009); received more PBSC (7 vs 0%, P = 0.03), more tacrolimus (12 vs 0%, P = 0.002), and less CsA (88 vs 97%, P = 0.02); and had fewer cases of aplastic anemia (1 vs 6%, P = 0.02) ( Table 1 ). The median day of introduction of ganciclovir prophylaxis differed significantly between the three-and the five-times-per-week groups due to a change in the definition of engraftment during the study period (day ϩ28 and day ϩ23, respectively; P Ͻ 0.001).
CMV infection
There was a significant difference in the probability of development of CMV infection in the three-and the fivetimes-per-week groups (41 and 21%, respectively; P = 0.005). Thirty-eight percent of the patients in the threetimes-per-week group shed CMV, as compared with 20% of the patients in the five-times-per-week group (P = 0.01). The most common site of virus isolation was from the bloodstream. Sixteen (26%) patients in the three-times-per- GCV = ganciclovir; PBSC = peripheral blood stem cell; TBI = total body irradiation; ATG = anti-thymocyte globulin.
All P values are Kaplan-Meier probability estimates.
week group had CMV isolated from blood vs 20 (17%) patients in the five-times-per-week group (P = 0.22). The median day of first shedding differed significantly among the two groups (51 days post transplant and 40 days post transplant, respectively; P = 0.04). The incidence of other life-threatening infections was similar in the two groups (30% and 30%, respectively; P = 0.99).
CMV disease
In the three-times-per-week group, CMV disease developed in 11 patients with nine episodes of pneumonia and two patients with GI disease ( Table 2 ). Five of the nine patients with pneumonia had extra-pulmonary CMV involvement in the GI system (two), adrenals (two), kidneys (one) and liver (one). One of the patients had pneumonia, GI, kidney, and adrenal involvement. In the five-times-per-week group, CMV disease developed in five patients, including three with pneumonia and two with GI disease. One patient had CMV pneumonia and involvement of the kidney.
There was a significant difference between the two groups in the probability of developing CMV disease. The Kaplan-Meier estimate for development of CMV disease from the start of ganciclovir to 100 days after transplant was 16 and 4% in the three-and the five-times-per-week groups, respectively (P = 0.004) (Figure 1 ). The probability of developing CMV pneumonia from the start of ganciclovir to day 100 after transplant was 13 and 2%, respectively (P = 0.004). The cumulative incidence of CMV disease in the three-times-per-week group was four-fold that of the five-times-per-week group. The median onset of CMV disease was 55 days (range 33-95 days) and 40 days (range 34-84 days), respectively (P = 0.46). This occurred even though the absolute number of CMV cases was less in the five-times-per-week group.
In the three-times-per-week group, CMV disease occurred in eight of 32 (25%) TCD patients (eight patients with pneumonia) vs three of the 46 (6.5%) non-TCD patients, including two patients with GI disease, one patient with pneumonia and two patients with GI disease (RR = 3.8, P = 0.02). In the five-times-per-week group CMV dis- ease developed in four of the 41 (10%) TCD patients (three patients with pneumonia and one patients with GI disease) and in one of the 96 (1%) non-TCD patients (one patients with GI disease) (RR = 8.9, P = 0.02).
Mortality rate
The Kaplan-Meier estimate of survival rate calculated from the day of introduction of ganciclovir prophylaxis to 100 days post transplant was 66% among the 78 patients receiving the three-times-per-week regimen and 76% among the 137 patients receiving the five-times-per-week regimen (P = 0.3). There was a significant difference in the CMVattributable mortality rate between the two groups (12 and 1.5%, respectively; P = 0.003). CMV disease was the cause of death in eight of the 11 cases of CMV disease in the three-times-per-week group and in two of the five cases of CMV disease in the five-times-per-week group. The CMV case-fatality ratio was 73 and 40% in the three-and the five-times-per-week groups, respectively (P = 0.30).
In the three-times-per-week group, the CMV-associated mortality was 28% in the TCD patients (eight of 32) and 2% in the non-TCD patients (one of 46). In the five-timesper-week group, the CMV-associated mortality was 5% in the TCD patients (two of the 41 patients died of CMV pneumonia) and 0% in the non-TCD patients.
Ganciclovir toxicity
Sixty-one percent of patients in both the three-times and five-times-per-week groups finished their course of ganciclovir without interruption (P = 0.97). Twenty-four percent of the three-times-per-week group (18 of 75) were changed to foscarnet. Ninety-three percent of the patients (17 of 18) were changed to foscarnet due to neutropenia from ganciclovir treatment or due to slow engraftment. Thirty-three percent of the five-times-per-week group (45 of 137) were changed to foscarnet. Ninety-three percent (42 of 45) were switched to foscarnet due to neutropenia.
Risk factors for CMV disease
In the univariate analysis, the three-times-per-week ganciclovir regimen (P = 0.004), the use of TCD marrow (P = 0.0006), and the occurrence of severe GVHD (P = 0.03) contributed to the risk of CMV disease. The use of TCD marrow was a univariate risk factor for development of CMV disease both in patients receiving the three-times-perweek (P = 0.02) and the five-times-per-week regimen (P = 0.02).
In the multivariate analysis, after controlling for all variables, the three-times-per-week regimen (RR = 5.7; P = 0.008), FK506 (RR = 14.7; P = 0.008), and TCD (RR = 14.71; P = 0.002) were all risk factors for CMV disease (Table 3A) . Because of the importance of acute GVHD as a risk factor for CMV disease in marrow transplant patients, a multivariate analysis was done with acute GVHD forced into the model (Table 3B ). Acute GVHD did not emerge from this model as a significant risk factor.
Discussion
The purpose of this study was to retrospectively review in a nonrandomized fashion the spectrum of CMV infection and disease of allogeneic marrow transplant patients at MD Anderson Cancer Center. This study reviewed records from 1991 to 1994, a period of time where there was a change in ganciclovir prophylaxis. Because of clinical concerns of an increase in CMV disease, ganciclovir prophylaxis was changed from three-to five-times-per-week. 19 Overall, the three-times-per-week regimen was associated with a four-fold increased risk for CMV disease compared with the five-times-per-week group. Ganciclovir prophylaxis given five-times-per-week was associated with an eight-fold decrease of CMV-attributable mortality compared with the three-times-per-week regimen. Patients who received the five-times-per-week regimen had a higher overall survival rate within 100 days post transplant; however, this trend was not statistically significant.
Even though patients were given prophylactic ganciclovir, there was a significant incidence of CMV infection and disease in the three-and the five-times-per-week groups. Thirty-eight percent of the patients in the three-times-perweek group shed CMV as compared with 20% of the patients in the five-times-per-week group. The Kaplan- Meier estimate for development of CMV disease from the start of ganciclovir to 100 days after transplant was 16 and 4% in the three-and the five-times-per-week groups. The probability of developing CMV pneumonia was 13% and 2%, respectively. The incidence of CMV infection and disease was greater than reported in the treatment arm of another ganciclovir prophylaxis study where the incidence of infection was 3% and there were no reported cases of pneumonia. 16 The incidence of CMV infection and disease were less than reported previously at this institution when patients received ganciclovir three-times-per-week, 19 but similar to another prophylactic regimen. 17 Previous studies have shown that ganciclovir prophylaxis given three-times-per-week may be effective in preventing CMV disease in allogeneic BMT recipients. [24] [25] [26] In one of these reports, the incidence of acute GVHD in the ganciclovir group was zero, vs 20% in the control group 25 while none of the three studies enrolled patients receiving T celldepleted transplants. [24] [25] [26] Because of the retrospective nature of this study and the separation in time of the ganciclovir schedules, there is the possibility that changes in practice or the patient population over time may be responsible for some of the difference in CMV disease. We do not think these changes or the chronological difference between the two groups detract from the finding that there was a decrease in CMV disease in the five-times-per-week group.
Our study suggests that three-times-per-week ganciclovir is not effective CMV prophylaxis in allogeneic marrow transplant patients who receive a TCD marrow. In the three-times-per-week group, CMV pneumonia occurred in eight of 32 (25%) TCD patients vs one of the 46 (2%) non-TCD. In the five-times-per-week group CMV pneumonia developed in three of the 41 (11%) TCD patients and none of the 96 (0%) non-TCD patients. Bunjes et al 27 showed an increased incidence of CMV infection and disease that did not achieve statistical significance in their patients receiving a TCD marrow transplant. In our study, TCD transplantion was an important risk factor for CMV disease in the multivariate analysis. Enright et al 28 also found that TCD was an important risk factor for CMV pneumonia in allogeneic marrow transplant patients. In their analysis, acute GVHD did not emerge as a risk factor for CMV pneumonia similar to our findings (Table 3B ). These data may reflect upon the importance of TCD as a significant risk factor or there were too few cases of acute GVHD to analyze due to the immunosuppressive effects of TCD.
Tacrolimus also emerged from the multivariate analysis as a risk factor for CMV disease. Tacrolimus is a macrolide derived from Streptomyces tsukubaensis and a potent immunosuppressive agent. Its mechanism of action is by inhibition of T cell proliferation by forming a complex with FK binding protein-12 thus preventing seronine-threonine phosphatase activity of calcineurin. This prevents upregulation of IL-2 transcription. 29 Tacrolimus has been associated with CMV retinitis, 30 an increase in EBV infection and lymphoproliferative disease in children under the age of five receiving a liver allograft. 31 Other studies have not confirmed these findings. 32 Our results are tempered by the small number of patients in this study who received tacrolimus and suggest a need to study further the relationship between tacrolimus and CMV disease.
Our study suggests that ganciclovir three-times-per-week is not effective for prophylaxis of CMV infection and disease especially in patients receiving a T cell-depleted transplant. Both T cell depletion and tacrolimus were found to be significant risk factors for CMV disease in the multivariate analysis while acute GVHD was not. The role of tacrolimus in infection after marrow transplant will require further study.
